Stock Analysis
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
Regeneron Pharmaceuticals, Inc. (REGN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Regeneron Pharmaceuticals, Inc. (REGN) currently has an AIQ Score of 69/100, indicating a neutral setup. Momentum is the strongest factor at 95/100. Value is the weakest current factor at 48/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
REGN at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $805.67 |
| AIQ Score | 69/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $84.87B |
| P/E Ratio (TTM) | 19.67 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $12.59 |
| Revenue (quarter ended 2026-06-30) | $4.29B |
| Dividend Yield (TTM) | 0.45% |
| Beta | 0.24 |
| Volume | 581.05K |
| 52-week range | $572.75-$859.34 |
| RSI 14 | 74.43 |
| 50-Day SMA | $790.97 |
| 200-Day SMA | $735.83 |
| Analyst Price Target | $827.40 |
| Next Earnings | Oct 30, 2026 |
REGNRegeneron Pharmaceuticals, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum95
- Value48
- Quality73
- Risk resilience61
- Sentiment—
REGN Stock Analysis Summary
Regeneron Pharmaceuticals, Inc. (REGN) currently has an AIQ Score of 69/100, indicating a neutral setup. Momentum is the strongest factor at 95/100. Value is the weakest current factor at 48/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, REGN has AIQ Score of 69/100 with Momentum base of 95/100 and fading Value at 48/100. Wait for component alignment before adding exposure.
Momentum (95/100) leads while Value (48/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.22% stock move · REGN classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is REGN Bullish or Bearish Right Now?
REGN currently has a neutral overall setup. Momentum is the strongest factor at 95/100, while Value is weakest at 48/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 73/100.
- - Momentum is constructive at 95/100.
- - Risk Resilience is supportive at 61/100.
- - Price is +1.86% above its 50-day SMA.
- - Analyst target implies +2.70% upside from the latest quote.
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
REGN's Technical Analysis Consensus is currently Strong Buy, with 34 buy, 1 neutral, and 10 sell votes. REGN's 14-day RSI is 74.43, which places the stock in an overbought momentum range. REGN's beta is 0.24, indicating lower market sensitivity than the broad market.
What Changed in REGN?
The largest recent change in REGN is Momentum moving up by 44.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the REGN Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
REGN Decision Framework
Public evidence layers, setup checks, and risk context for Regeneron Pharmaceuticals, Inc..
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
Regeneron Pharmaceuticals, Inc. has an AIQ Score of 69/100 in a Neutral regime. Momentum is strongest at 95/100. Beta is 0.24, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | REGN is in a Neutral AIQ regime with score 69/100. |
| Signal Conflict | The primary conflict is that momentum leads at 95/100 while value lags at 48/100. |
| Factor Evidence | Momentum 95/100 · Value 48/100 · Quality 73/100 · Risk 61/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 95/100.
Momentum is 95/100 and RSI (14) is 74.4.
REGN is in a Neutral regime at 69/100.
Risk factor is 61/100 with beta 0.24 and annual volatility 33.45%.
Current conflict: momentum leads at 95/100 while value lags at 48/100.
REGN Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
REGN Fundamentals
REGN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
REGN Technical Analysis
REGN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
REGN Stock Catalysts
Track REGN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
REGN Dividend Analysis
REGN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
REGN Financial Data
REGN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
REGN Risk Analysis
REGN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
REGN Stock News
REGN stock news, market tone, recent headlines, and catalyst context.
REGN vs Large Cap Pharma Peers
Current peer cohort: REGN · RPRX · TEVA · VRTX · ABBV. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| REGN Current stock | 69/100 | 48/100 | 95/100 | 61/100 | 1.05 | 33.45% | Current |
| RPRX Royalty Pharma | 59/100 | 51/100 | 80/100 | 51/100 | 2.19 | 23.74% | REGN vs RPRX |
| TEVA Teva Pharmaceutical | 56/100 | 65/100 | 72/100 | 54/100 | 1.98 | 39.26% | REGN vs TEVA |
| VRTX Vertex Pharmaceuticals | 63/100 | 32/100 | 76/100 | 63/100 | 0.79 | 28.99% | REGN vs VRTX |
| ABBV AbbVie | 56/100 | 36/100 | 82/100 | 44/100 | 0.77 | 25.89% | REGN vs ABBV |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 22, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching REGN
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for REGN
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
REGN Stock FAQ
What is REGN stock price today?
Regeneron Pharmaceuticals, Inc.'s current stock price is $805.67. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is REGN bullish or bearish right now?
REGN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is REGN's market cap?
REGN's market cap is $84.87B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is REGN's current P/E ratio?
REGN's current P/E ratio is 19.67 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is REGN's RSI?
REGN's 14-day RSI is 74.43 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is REGN above its 50-day and 200-day moving averages?
REGN is 1.86% from its 50-day SMA and 9.49% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is REGN's next earnings date?
REGN's next earnings date is currently listed as Oct 30, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does REGN pay a dividend?
REGN's dividend yield is 0.45% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.